1. Extend your research by partnering with
MTTlab - an expert in testing services for the
biomedical, biotechnological,
pharmaceutical and food & beverage
industries.

2. MTTlab offers testing services in the biomedical,
biotechnological, pharmaceutical and food & beverage fields,
as well as providing assistance with early to mid-stage drug
development both in-vitro and in-vivo. MTTlab assists clients
in fulfilling their needs and requirements in the Research &
Development field of Cellular and Molecular Biology,
Biochemistry and Pharmacology.
MTTlab services are available worldwide to private
companies, academic institutions and government research
centers.
MTTlab’s competitive flat rate price structure allows
compound in vivo testing already during the research phase.
MTTlab can follow up promising compounds from these early
tests during the preclinical development program.
Relying on the network of companies we have created,
MTTlab offers complete one stop preclinical drug
development packages creating best value for highest return
of investment.

3. Services Available
 In vivo Studies (toxicology, efficacy, behavioural, disease
models) on mice.
 Preclinical in vivo evaluation of the anti-tumor activity of
a test compound.
 In vitro testing (Cytotoxicity)
 Molecular Biology, Biomarker Assay
 Medical Device Testing (both in vivo and in vitro)
 Testing and Certification of Food & Beverages and
Functional Food products

4. In Vitro Studies
MTTlab provides clients with reproducible and consistent in
vitro assay platforms, expertise in standard or custom assay
design and implementation, approximately 40 cell lines
available in-house (custom cell lines may be provided by the
client). The most requested assay platforms include Cell
proliferation and cytotoxicity (IC50/IC90 determination) using
Sulforhodamin B (total protein assay), Resazurin
(fluorescence cell metabolic assay) or MMT (cell metabolic
assay). Cell culture assay gives a rapid and lower cost
evaluation of drug activity in a range of tumors, as well as
minimizing the risk of failure of in vivo assays.

5. Cell viability assay (IC50, IC90 testing):
Cells: most standard cell lines are available. If the sponsor
requires a specific cell line not available in house, MTTlab can
either purchase it on behalf of the sponsor (direct costs only)
or the cell line can be provided directly by the sponsor (with
negative Cell Contamination Test). A growth curve is
established first for new cell lines.
Assay: Cell viability assay is offered with the option of various
readouts such as SRB (NCI standard test), Resazurin, MTT or
in situ Western Blot (with additional charge for antibody and
Ab testing). The default format (subject to customization) is
96-well plate format, up to 5 compounds, nine two-fold
dilution steps and eightfold testing of each concentration.
Standard readout statistics are provided.

6. In Vivo Studies
MTTlab specializes in carrying out and evaluating preclinical
tests of novel oncological compounds and medical devices.
MTTlab offers small/medium size (up to 500 mice in a single
experiment) in vivo studies (toxicology, efficacy, behavioural,
disease models, biodistribution) and relevant in vitro studies.
In vivo oncology testing
MTTlab offers following experimental models:
 Xenografts
 Allografts
 Metastasis, Leukemia and Lymphoma,
 Orthotopic Experiments upon request (not included in
the flat rate package)
 Toxicology Testing DRF in mice.
Please enquire for more extended toxicology studies
Various in vivo tumor models are available. All in vivo tumor
experiments use tumor fragment-based technology or in vivo
propagated (i.p.) tumors. Each animal is identified via micro-
chip and randomization into experimental groups is
performed according to the highest standards.

7. In standard experiments, 7 to 12 mice are used per test
group and each experiment includes a vehicle and selected
chemotherapeutic control groups. As per sponsor request,
smaller groups and/or more diverse compounds can be
tested in a single Study. MTTlab calculates the study cost
according to the number of mice and no setup fee is added.
“Ready-to-Use” tumor models are shown in the table below;
lead time can be as short as 4 weeks from order to first
treatment. Please inquire for other models.
Syngenic tumors
Tumor origin Cell lines
Metastasis
site
Arteficial
metastasis
Spontaneous
metastasis
Lung
Lewis
lung
lung i.v. s.c.
Ovarian Reticulum
Sarcoma
M5076 liver i.v.
Breast 4T1 lung i.v. s.c.
Skin Melanoma B16F1 lung, liver
i.v., intra-
splenic
s.c.

8. Xenografts
Primary tumor origin Cell lines Tumor-source
Liver (HCC) HEP G2, HEP B3 fragment
Cervical cancer (HPV+) CaSki, ME180, MS751, Siha fragment
Lung (NSCLC) A549 fragment
Melanoma A375 (B-Raf V600E) fragment
Kidney Caki-1, 786-0 fragment
Colon HT-29, HCT116 p53 +/+, HCT116 p53 -/- fragment
Ovary Skov-3, OVCAR3, IGROV3, fragment
Pancreas PANC1, MiaPaCa-2 fragment
Bladder RT112, RT112 D21 (doxo-reisistant) fragment
Ewing Sarcoma TC-71, CADO-ES1, SK-N-MC, C-433 fragment
Neuroblastoma GI-LIN, SY5Y, Lan5, IMR32 fragment

9. Ex vivo oncology testing
MTTlab provides clients with a comprehensive package of ex
vivo tests. Tumor bearing mice are treated with anti-tumor
drug. The tumors are isolated and specific tests are designed
by the client or MTTlab for mode-of-action studies in tumor
tissue. These tests can also serve as the basis for biomarker
studies and to stratify patient populations for subpopulations
most likely to respond to therapy. Client tailored experiments
can be designed employing in vivo tumors in mice either
from cell culture or primary tumor sources.
Various in vivo tumor models are available, and all in vivo
tumor experiments are performed using:
 tumor fragment based technology or in vivo propagated
(i.p.) tumors;
 animals marked with micro-chips;
 meticulous randomization into experimental groups
according to the highest standards;

10. General workflow of an ex vivo experiment:
1. Tumors in mice are induced by using either cell culture
or primary tumor source.
2. Tumor bearing mice are treated with anti-neoplastic
agents.
3. Tumors are isolated and processed according to the
client's request (see below).
4. Specific tests designed by either MTTlab or the client are
used to analyze tumor tissue.
5. Tests are designed to establish anti- neoplastic agent
mode-of-action, a basis for biomarker studies or to
identify patient subpopulations most likely to respond
to therapy.
Post-treatment tumor can be processed (and delivered) as:
 Frozen tumor
 Paraffin embedded tumor
 Tumor extract (ready for WB, total extract, enriched
fractions for nucleus, cytoplasm, chromatographic
fractions)
 RNA/DNA prepared for sequencing, microarray and PCR

11. Food & Beverage, Nutraceutical Certification
MTTlab is also active in the field of testing and certifying food
products, beverages and functional food (Nutraceuticals)
products.
Please contact us for further details.
Phone: +39 040 375 7821
e-mail: info@mttlab.eu

12. MTTlab Srl
Via Giustiniano 8
34133 – TRIESTE (TS) – Italy
Phone: +39 040 375 7821
e-mail: info@mttlab.eu
PEC: mttlabsrl@pec.it
web: www.mttlab.eu
MTTlab offers:
 Biotechnology
 Consulting Services
 CRO (Contract Research Organization)
 In vitro diagnostics
 Medical Research
 Medical Technology / Biomedical Engineering